GC
DNLI icon

Guggenheim Capital’s Denali Therapeutics DNLI Stock Holding History

Guggenheim Capital’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$351K Sell
13,636
-189
-1% -$3.88K ﹤0.01% 1439
2026
Q1 		$265K Buy
13,825
+1,357
+11% +$27K ﹤0.01% 1429
2025
Q4 		$206K Sell
12,468
-37,057
-75% -$626K ﹤0.01% 1679
2025
Q3 		$719K Sell
49,525
-2,335
-5% -$33.6K 0.01% 1039
2025
Q2 		$726K Sell
51,860
-4,152
-7% -$58.4K 0.01% 1011
2025
Q1 		$762K Buy
56,012
+7,881
+16% +$151K 0.01% 1000
2024
Q4 		$981K Buy
48,131
+27,518
+133% +$704K 0.01% 933
2024
Q3 		$600K Buy
20,613
+694
+3% +$17.2K ﹤0.01% 1335
2024
Q2 		$463K Buy
19,919
+200
+1% +$3.84K ﹤0.01% 1468
2024
Q1 		$405K Buy
19,719
+2,323
+13% +$43.7K ﹤0.01% 1558
2023
Q4 		$373K Sell
17,396
-39,974
-70% -$792K ﹤0.01% 1577
2023
Q3 		$1.18M Buy
57,370
+3,584
+7% +$90.9K 0.01% 1028
2023
Q2 		$1.59M Sell
53,786
-2,458
-4% -$69.1K 0.01% 954
2023
Q1 		$1.3M Sell
56,244
-8,447
-13% -$232K 0.01% 1047
2022
Q4 		$1.8M Buy
64,691
+14,256
+28% +$424K 0.02% 894
2022
Q3 		$1.55M Sell
50,435
-10,572
-17% -$344K 0.01% 948
2022
Q2 		$1.79M Buy
61,007
+6,580
+12% +$172K 0.01% 936
2022
Q1 		$1.75M Buy
54,427
+7,445
+16% +$256K 0.01% 1086
2021
Q4 		$2.1M Buy
+46,982
New +$2.23M 0.01% 1035

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Guggenheim Capital's DNLI Position: Q2 2026 in Review

Guggenheim Capital reduced its Denali Therapeutics (DNLI) stake by 1.4% in Q2 2026, selling an estimated $3.88K and leaving 13,636 shares worth $351K. The position accounts for ﹤0.01% of the portfolio, ranked #1439.

Guggenheim Capital first reported a position in DNLI in Q4 2021 and has held it in 19 quarters since. The position peaked at $2.1M in Q4 2021. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Guggenheim Capital held 13,636 shares of Denali Therapeutics worth $351K as of Q2 2026.
  • Guggenheim Capital sold 189 Denali Therapeutics shares in Q2 2026, an estimated $3.88K.
  • Denali Therapeutics made up ﹤0.01% of Guggenheim Capital's portfolio in Q2 2026, its #1439 holding.
  • Guggenheim Capital first reported a position in Denali Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Guggenheim Capital's Denali Therapeutics position peaked at $2.1M in Q4 2021.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.